FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC

Table 1 Patient characteristics n(%)

Ref.	Year of publication	n	Age,yr	M/F	Study type	Study protocol FDG response	Stage ofdisease	Histology	EGFR Selection
Riely et al[20]	2007	13	56	2/11	Prospective	21 d after stopping and 21 d after restarting	IV	Adenocarcinoma 11 (85) Other (including NOS) 2 (15)	Only EGFR mutated tumors
Aukema et al[21]	2010	23	63	8/15	Prospective	After 7 d	I-III	Adenocarcinoma 17 (73) Other 6 (26)	No selection
Mileshkin et al[11]	2011	51	61	30/21	Prospective	After 14 d and 56 d	III - IV	Adenocarcinoma 37 (72) Squamous cell carcinoma 8 (16) Large-cell carcinoma 1 (2) Other (including NOS) 5 (10)	No selection
Zander et al[22]	2011	34	61	17/17	Prospective	After 7 d and 42 d	IV	Adenocarcinoma 26 (76) Squamous cell carcinoma 4 (12) Large cell carcinoma 1 (3) Bronchioloalveolar carcinoma 3 (9)	No selection
Benz et al[23]	2011	22	64	6/16	Prospective	After 14 d and 78 d	III - IV	Adenocarcinoma 17 (78) Squamous cell carcinoma 3 (14) Other (including NOS) 1 (4) Large cell carcinoma 1 (4)	No selection
O'Brien et al[24]	2012	47	63	18/29	Prospective	After 42 d	III - IV	Adenocarcinoma 28 (60) Squamous cell carcinoma 6 (13) Bronchioalveolar carcinoma 7 (14) Other (including NOS) 6 (13)	No selection
Takahashi et al[25]	2012	20	69	5/15	Prospective	After 2 d and 28 d	III - IV	Adenocarcinoma 20 (100)	No selection

FDG: [18F]-fluorodeoxyglucose; EGFR: Epidermal growth factor receptor.

Table 2 Early [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography reponse results \< 21 d

Ref.	Year ofpublication	n	SUV	Responsecriteria	FDG response time	Cut-offvalue	FDG response, n (%)	FDG-PET/CT vs RECIST	PFS	OS
Riely et al[20]	2007	13	Max	EORTC	21 d	15%	PR 6 (46) SD 7 (54)
Aukema et al[21]	2010	22	Max	EORTC	7 d	25%	PR 6 (26) SD 16 (70) PD 1 (4)
Mileshkin et al[11]	2011	51	Max	EORTC	14 d	15%	PR 13 (26) SD 17 (33) PD 21 (41)	FDG PR: PR 4 SD 7 PD 2 FDG SD: PR 0 SD 12 PD 5 FDG PD: PR 0 SD 7 PD 14	R 5.5 mo NR 2.5 mo	R 11.6 mo NR 7.6 mo
Zander et al[22]	2011	34	Peak	EORTC	7 d	30%	PR 8 (24) SD/PD 26 (76)	FDG PR: PR/SD 6 PD 2 FDG SD/PD: PR/SD 5 PD 21	R 7.8 mo NR 1.5 mo	R 16.1mo NR 3.4mo
Benz et al[23]	2011	22	Max	PRECIST	14 d	30%	PR 6 (27) SD 7 (32) PD 9 (41)		R 11.1 mo NR 2.4 mo	R 16.4 mo NR 14.7 mo
Takahashi et al[25]	2012	20	Max	EORTC	2 d	25%	PR 10 (50) SD 8 (40) PD 2 (10)	FDG PR: PR 8 SD 2 PD 0 FDG SD: PR 2 SD 5 PD 1 FDG PD: PR 0 SD 1 PD 1	R 10.4 mo NR 1.7 mo

FDG: [¹⁸F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography; RECIST: Response Evaluation Criteria in Solid Tumors; PFS: Progression free survival; EORTC: European Organization for Research and Treatment of Cancer.

Table 3 Late [¹⁸F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography response > 21 d

Ref.	Year ofpublication	n	SUV	Responsecriteria	Cut-offvalue	FDG response time	FDG Responsen (%)	FDG-PET vs RECIST	PFS	OS
Mileshkin et al[11]	2011	51	Max	EORTC	15%	56 d	PR 8 (16) SD 12 (23) PD 31 (61)	FDG PR: PR 4 SD 4 PD 0 FDG SD: PR 0 SD 11 PD 1 FDG PD: PR 0 SD 11 PD 20	R 6.5 mo NR 2.7 mo	R 11.9 mo NR 7.6 mo
Zander et al[22]	2011	34	Peak	EORTC		42 d	n/a	n/a
Benz et al[23]	2011	22	Max	PRECIST		78 d	n/a	n/a
O'Brien et al[24]	2012	47	Max	EORTC	25%	42 d	PR 15 (32) SD 8 (17) PD 15 (32) NE 9 (19)	FDG PR: PR 11 SD 2 PD 2 FDG SD: PR 0 SD 4 PD 4 FDG PD: PR 0 SD 2 PD 7
Takahashi et al[25]	2012	20	Max	EORTC		28 d	n/a	n/a

FDG: [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography; RECIST: Response Evaluation Criteria in Solid Tumors; PFS: Progression free survival; EORTC: European Organization for Research and Treatment of Cancer; n/a: Not applicable.

Table 4 Epidermal growth factor receptor

Ref.	Year of publication	n	EGFR selection	EGFR mutation (n)	Cut-off value	FDG	PFS
Riely et al[20]	2007	13	Only EGFR mutated tumors	8	n/a
Aukema et al[21]	2010	22	No selection	4	25%
Milishkin et al[11]	2011	51	No selection	4	> 15%	EGFR + PR 3 PD 2 SD 0 EGFR - PR SD PD
Zander et al[22]	2011	34	No selection	4			EGFR + 6.4 mo EGFR - 1.6 mo
Benz et al[23]	2011	22	No selection	5
O'Brien et al[24]	2012	47	No selection	11
Takahashi et al[25]	2012	20	No selection	12		EGFR+ PR 8 SD 3 PD 1 EGFR- PR SD PD

EGFR: Epidermal growth factor receptor; FDG: [¹⁸F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography; PFS: Progression free survival; n/a: Not applicable.